From: ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Characteristics | Case (n = 170) | Negative | Positive | P |
---|---|---|---|---|
Menopause | 0.144 | |||
Yes | 68 | 16(38.23%) | 52(76.47%) | |
No | 102 | 15(14.71%) | 87(85.29%) | |
Gravidity | 0.212 | |||
< 3 | 36 | 4(11.11%) | 32(88.89%) | |
≥ 3 | 134 | 27(20.15%) | 107(79.85%) | |
Clinical stage | 0.224 | |||
I | 116 | 24(20.69%) | 92(79.31%) | |
IIA | 54 | 7(12.96%) | 47(87.04%) | |
Tumor diameter | 0.000** | |||
≤ 4 cm | 96 | 27(28.13%) | 69(71.88%) | |
> 4 cm | 74 | 4(5.41%) | 70(94.59%) | |
Keratinization | 0.079 | |||
Yes | 90 | 12(13.33%) | 78(86.67%) | |
No | 80 | 19(23.75%) | 61(76.25%) | |
Horizontal diffusion diameter | 0.000** | |||
≤ 4 cm | 102 | 28(27.45%) | 74(72.55%) | |
> 4 cm | 68 | 3(4.41%) | 65(95.59%) | |
Stroma invasion | 0.612 | |||
Superficial stroma | 8 | 2(25.00%) | 6(75.00%) | |
Deep stroma | 162 | 29(17.90%) | 133(82.10%) | |
Vascular invasion | 0.008* | |||
Negative | 36 | 12(33.33%) | 24(66.67%) | |
Positive | 134 | 19(14.18%) | 115(85.82%) | |
Lymph node metastasis | 0.076 | |||
Negative | 54 | 14(25.93%) | 40(74.07%) | |
Positive | 116 | 17(88.73%) | 99(85.34%) | |
Parametrial invasion | 0.023* | |||
Negative | 126 | 28(22.22%) | 98(77.78%) | |
Positive | 44 | 3(6.82%) | 41(93.18%) | |
Parametrial margin | 0.855 | |||
Negative | 152 | 28(18.42%) | 124(81.58%) | |
Positive | 18 | 3(16.67%) | 15(83.33%) | |
Vagina margin | 0.001** | |||
Negative | 80 | 23(28.75%) | 57(71.25%) | |
Positive | 90 | 8(88.89%) | 82(91.11%) | |
Histological grade | 0.318 | |||
G1 | 30 | 6(20.00%) | 24(80.00%) | |
G2 | 52 | 6(11.54%) | 46(88.46%) | |
G3 | 88 | 19(21.59%) | 69(78.41%) | |
HPV infection | 0.955 | |||
Negative | 16 | 3(18.75%) | 13(81.25%) | |
Positive | 154 | 28(18.18%) | 126(81.82%) | |
PNI | 0.011* | |||
Negative | 31 | 31(100.00%) | 0(0.00%) | |
Positive | 139 | 114(82.01%) | 25(17.99%) |